immunotoxin

(redirected from Immunotoxins)
Also found in: Medical, Encyclopedia.

im·mu·no·tox·in

 (ĭm′yə-nō-tŏk′sĭn, ĭ-myo͞o′-)
n.
A hybrid molecule formed by binding a toxin to a monoclonal antibody, used to destroy tumor cells.

immunotoxin

(ˌɪmjʊnəʊˈtɒksɪn)
n
a toxin with immunosuppressive effects

im•mu•no•tox•in

(ˌɪm yə noʊˈtɒk sɪn, ɪˌmyu-)

n.
a monoclonal antibody linked to a toxin with the intention of destroying a specific target cell while leaving adjacent cells intact.
[1985–90]
Mentioned in ?
References in periodicals archive ?
Among immunotherapeutic agents, immunotoxins are a class of antibody-conjugated agents that have been developed for clinical application in many malignancies.
2001) Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Generally, different means have been exploited in T reg suppression by researchers such as chemical drugs (9,11,12), anti CD25 monoclonal anti body (13,14), immunotoxins [Denileukin diftitox (ONTAK) and LMB-2 (single chain fragment variable anti-tacfused with bacterial Pseudomonas exotoxin A)] (1,8,15) and anti T reg vaccination targeting FoxP3 (3).
Molecular Templates, a venture-backed biopharmaceutical company that develops next-generation immunotoxins for the treatment of cancer and other serious diseases, has signed a Preferred Provider Agreement with Veristat, a full service Clinical Research Organisation, it was reported on Tuesday.
Ochratoxins are powerful nephrotoxins carcinogens teratogens and immunotoxins especially in rats and human beings (Yenilmez et al.
In recent years, technological progress allowed construction of MoAbs other than their classical forms: for example, conjugated with radionucleotides, immunotoxins, or bispecific antibodies.
Keynote Presentation: "Novel Approach to B and T Epitope Removal from Immunotoxins with Retention of High Cytotoxic Activity," featuring Ira Pastan, M.
Oncomatrix carries out the development of Diagnostic devices and Antibody-Drug Conjugates and Immunotoxins against these novel targets, in collaboration with reference research centers, universities and hospitals in Europe and USA, such as National Jewish Health, Case Western Reserve University, University of Stuttgart, Hospital Universitario Marques de Valdecilla and Hospital Central de Asturias.
Topics covered in-depth in the 11 fellowship modules include the following: the molecular biology of cancer; genetic and viral predispositions; tumor profiling, individualized chemotherapy, antioxidant therapy, leading-edge radiation therapy, chemotherapy (old and new drugs), stem-cell transplantation, and off-label pharmaceuticals in cancer treatment; immunosuppression, immunodeficiency, immunotoxins, and interferon therapy; assessment and treatment of therapy-induced conditions; promising emerging treatment including avemar therapy, cancer pH manipulation therapy, Coley's toxins, Hoxsey therapy, hyperbaric oxygen therapy, hyperthermia, photodynamic treatment, protocell therapy, and sonodynamic therapy; dietary interventions; and herbal supplementation.
In contrast, ECCN 1C991, which includes certain vaccines, immunotoxins, medical products, and diagnostic and food testing kits, is controlled generally for anti-terrorism reasons, and to a more limited group of countries than 1C351 items.
They then introduced special antibodies with toxins and found that the immunotoxins penetrated the leukaemia cells and killed them faster.